Moderna, Inc. recently revealed that the company is actively planning its future product pipeline, and it is expected that as many as three new vaccine products may be launched between 2027 and 2028.

These potential new products include a combined vaccine that protects against both influenza and COVID-19, an updated vaccine for seasonal influenza, and a new vaccine designed to prevent norovirus infection. This plan highlights Moderna’s ongoing expansion and in-depth application of its mRNA technology platform. The company is committed to extending its core mRNA research and development capabilities from the successful response to the COVID-19 pandemic to a broader range of respiratory and even gastrointestinal infectious diseases. If the combined influenza and COVID-19 vaccine is successfully launched, it could simplify public health immunization procedures and provide people with more convenient and comprehensive protection options. The development of a norovirus vaccine marks an important step for the company into a new field of disease prevention.Market analysts have pointed out that if this product pipeline plan progresses smoothly, it could open up new growth opportunities for Moderna in the coming years and strengthen its leading position in the global biotechnology and vaccine sectors. Investors are closely monitoring the progress of these research and development projects as well as their commercialization prospects.